Friday, 14 Dec 2018

You are here

Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks

Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks. FDA approved lanadelumab (Takhzyro) is a monoclonal antibody that inhibits plasma kallikrein, and in this study demonstrates its ability to significantly prevent hereditary angioedema attacks.

There is a significant unmet need for effective therapy in hereditary angioedema as existing therapies have significant limitations and toxicities. 

This multicenter, randomized clinical trial included 125 patients with hereditary angioedema type I or II, who were randomiized 2:1 to lanadelumab or placebo for 26 weeks.  Subcutaneous lanadelumab was given as 150 mg every 4 weeks (n = 28) or 300 mg every 4 weeks (n = 29) or 300 mg every 2 weeks (n = 27).

A total of 90% of patients completed the study. Prior to randomization, the mean number of hereditary angioedema attacks per month ranged from 3.2 to 4.0 per month.

Lanadelumab reduced the mean attack rate by 73-87% compared to placebo.  The attack rates in this 26 week trial were:

  • placebo 1.97 attacks/month
  • lanadelumab 150-mg q 4 weeks 0.48 attacks/month
  • lanadelumab 300-mg  q 4 weeks 0.53 attacks/month
  • lanadelumab 300-mg q 2 weeks 0.26 attacks/month

The most common adverse events were injection site reactions (34.1% placebo, 52.4% lanadelumab) and dizziness (0% placebo, 6.0% lanadelumab).

These findings support the use of lanadelumab as a prophylactic therapy for hereditary angioedema. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Biosimilar Rituximab for NHL, not RA

The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.

First FDA Approved Drug for HLH

The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.

Emapalumab (Gamifant), manufactured by Novimmune SA, may be used in all patients (including newborns and older children) "who have refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy," the FDA said.

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.